^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) + anastrozole (Aromatase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Overall survival outcomes of combination anastrozole and fulvestrant in molecular subsets of hormone receptor-positive breast cancer
Published date:
11/17/2020
Excerpt:
We reviewed charts of 118 pts with advanced HR+ BC who received A+F...We compared TTF and OS outcomes in pts with and without molecular aberrations including HER2 overexpression/amplification, or mutations in PIK3CA, ESR1 or BRCA1/2….Median TTF was 23 months for control vs.14 months for PIK3CA mutant (HR: 0.89; 95% CI: 0.40 -1.95, p = 0.76). Median OS was not reached for control vs. 44 months for PIK3CA mutant (HR: 0.50; 95% Cl: 0.16 - 1.56, p = 0.23).
